SCHEMBL667165

SCHEMBL667165

O=C(O)C=CC=CC=CC(O)CCCCCCCCCCCCO

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.65
BACE1 P56817 1/20 0.65
PPARG P37231 2/20 0.43
FPR2 P25090 2/20 0.43
GPR132 Q9UNW8 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
OXER1 Q8TDS5 1/20 0.43
CMKLR1 Q99788 1/20 0.41
FAAH O00519 3/20 0.40
TRPA1 O75762 1/20 0.40
DDAH1 O94760 1/20 0.40
GAPDH P04406 1/20 0.40
MAPT P10636 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30072208 1.00 ACHE (0.65) ACHEBACE1PPARGFPR2GPR132
SCHEMBL6129416 1.00 ACHE (0.65) ACHEBACE1PPARGFPR2GPR132
SCHEMBL21049245 0.98 ACHE (0.67) ACHEBACE1PPARGFPR2GPR132
SCHEMBL23647621 0.98 ACHE (0.67) ACHEBACE1PPARGFPR2GPR132
SCHEMBL29256074 0.98 ACHE (0.67) ACHEBACE1PPARGFPR2GPR132
SCHEMBL16797495 0.91 ACHE (0.58) ACHEBACE1PPARGGPR132FAAH
SCHEMBL4759937 0.85 ACHE (0.49) ACHEBACE1PPARGGPR132FAAH
SCHEMBL649787 0.85 ACHE (0.49) ACHEBACE1PPARGGPR132FAAH
SCHEMBL4745520 0.85 ACHE (0.49) ACHEBACE1PPARGGPR132FAAH
SCHEMBL15287182 0.85 ACHE (0.49) ACHEBACE1PPARGGPR132FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023146984-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2023-08-03 WO claimed
CN-115768873-A Viable cell constructs for biosynthesizing dairy products, and products and methods related thereto 谢恩·吉利亚诺 2023-03-07 CN claimed
US-20230059978-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS GUILIANO SHAYNE (US) 2023-02-23 US claimed
EP-4087915-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS Guiliano, Shayne (US) 2022-11-16 EP claimed
WO-2021214048-A1 DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND 5-LIPOXYGENASE Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) 2021-10-28 WO claimed
WO-2021142241-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS GUILIANO SHAYNE (US) 2021-07-15 WO claimed
CN-111454246-A Soluble epoxide hydrolase inhibitors and uses thereof X-化学有限公司 2020-07-28 CN claimed
CN-110898050-A Application of 14, 15-epoxy eicosatrienoic acid in preparing medicament for treating depression and/or anxiety 南方医科大学 2020-03-24 CN claimed
CN-107074771-B Soluble epoxide hydrolase inhibitors and uses thereof X-化学有限公司 2020-03-20 CN claimed
US-20180362499-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2018-12-20 US claimed
US-7695927-B2 Detection of hypertension using glucuronidated metabolic products DETROIT R & D (US) 2010-04-13 US claimed
WO-2007111601-A1 DETECTION OF HYPERTENSION USING GLUCURONIDATED METABOLIC PRODUCTS DETROIT R & D., INC. (US) 2007-10-04 WO claimed
US-20060211064-A1 Detection of hypertension using glucuronidated metabolic products DETROIT R & D 2006-09-21 US claimed
US-6916843-B1 Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-07-12 US claimed
EP-1207877-A4 ANTI-INFLAMMATORY ACTIONS OF CYTOCHROME P450 EPOXYGENASE-DERIVED EICOSANOIDS BRIGHAM & WOMENS HOSPITAL (US) 2004-06-09 EP claimed
US-6693130-B2 UREAS, AMIDES, AND CARBAMATES; DICYCLOHEXYL UREA REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-02-17 US claimed
US-6534282-B2 Measurement concentration of hydroxyeicostrienoic acid DETROIT R&D, INC. 2003-03-18 US claimed
US-6440682-B1 ASSESSING HYPERTENSION BY MEASURING THE AMOUNT OF FREE AND CONJUGATED HYDROXYEICOSATRIENOIC ACIDS (DHETS) AND METABOLITES OF DHETS, WHICH ARE METABOLITES OF ARACHIDONIC ACID EPOXYGENASES AND EPOXIDE HYDROLASES DETROIT R&D INC. 2002-08-27 US claimed
EP-1207877-A1 ANTI-INFLAMMATORY ACTIONS OF CYTOCHROME P450 EPOXYGENASE-DERIVED EICOSANOIDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2002-05-29 EP claimed
WO-2001010438-A1 ANTI-INFLAMMATORY ACTIONS OF CYTOCHROME P450 EPOXYGENASE-DERIVED EICOSANOIDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2001-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180362499-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USES THEREOF EPHX1, EPHX2, LTA4H ACHE 875/4885BACE1 904/4885PPARG 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.